The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies....
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #AGA--The latest AGA clinical practice guideline acknowledges the role that TissueCypher can play identifying high-risk Barrett's esophagus patients....
We have narrowed our search to five small-cap biotech stocks with strong potential for the rest of 2024. These are: ARQT, BCYC, CSTL, PRME, LXRX....
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences reports inducement grants under Nasdaq Listing Rule 5635(c)(4)....
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle's founder, president & CEO, Derek Maetzold, has been named an EY 2024 Entrepreneur Of The Year® for the Gulf South region....
Here is how Castle Biosciences, Inc. (CSTL) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year....
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ASCO--Castle will present new data related to its DecisionDx-Melanoma and DecisionDx-UM tests at the 2024 ASCO Annual Meeting, May 31-June 4, 2024....
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced the publication of a study demonstrating the impact of the DecisionDx-SCC test in guiding adjuvant radiation therapy decision-maki...
The average of price targets set by Wall Street analysts indicates a potential upside of 36.2% in Castle Biosciences (CSTL). While the effectiveness of this highly sought-after metric is questionable,...